An endoscopic study of gastroduodenal lesions induced by nonsteroidal anti-inflammatory drugs

Clinical Therapeutics

Volumn 21, Issue 6, 1999, Pages 992-1003

  Cheatum, Don E ^e   Arvanitakis, Constantine ^a   Gumpel, Michael ^b   Stead, Helen ^c   Geis, G Steven ^d  

^a AHEPA UNIVERSITY HOSPITAL   (Greece)

^b NORTHWICK PARK HOSPITAL   (United Kingdom)

^c Searle Medical Department   (United Kingdom)

^d PFIZER INC   (United States)

^e NONE

Author keywords

Gastroduodenal lesions; Nonsteroidal anti inflammatory drugs; Osteoarthritis; Rheumatoid arthritis

Indexed keywords

ACETYLSALICYLIC ACID; DICLOFENAC; ETODOLAC; FENOPROFEN; FLURBIPROFEN; IBUPROFEN; INDOMETACIN; KETOPROFEN; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PIROXICAM; SULINDAC;

ADULT; AGED; ANTIINFLAMMATORY ACTIVITY; ARTICLE; DRUG EFFECT; DRUG TOLERABILITY; ENDOSCOPY; FEMALE; GASTRODUODENAL ULCER; GASTROINTESTINAL DISEASE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; RHEUMATOID ARTHRITIS; RISK FACTOR;

EID: 0032795602     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(99)80020-4     Document Type: Article

References (31)

1. 1. Burch JW, Stanford N, Majerus PW. Inhibition of platelet prostaglandin synthetase by oral aspirin. J Clin Invest. 1978;61:314-319.
2. 2. Schafer AI. Effects of nonsteroidal antiinflammatory drugs on platelet function and systemic hemostasis. J Clin Pharmacol. 1995;35:209-219.
3. 3. Langman MJS. Epidemiologic evidence on the association between peptic ulceration and antiinflammatory drug use. Gastroenterology. 1989;96:640-646.
4. 4. Fries JF. NSAID gastropathy: Epidemiology. J Musculoskelet Med. 1991;8:21-28.
5. 5. Gabriel SE, Jaakkimainen L, Bombardier C. Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs: A meta analysis. Ann Intern Med. 1991;115:787-796.
6. 6. Hawkey CJ. Non-steroidal anti-inflammatory drugs and peptic ulcers facts and figures multiply but do they add up? BMJ. 1990;300:278-284.
7. 7. Garciá-Rodríguez LA, Jick H. Risk of upper gastrointestinal bleeding and perforation associated with non-steroidal anti-inflammatory drugs. Lancet. 1994;343:769-772.
8. 8. Fenn GC. Controversies in NSAID-induced gastroduodenal damage - do they matter? Aliment Pharmacol Ther. 1994; 8:15-26.
9. 9. Langman MJ, Weil J, Wainwright P, et al. Risks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs. Lancet. 1994;343:1075-1078.
10. 10. MacDonald TM, Morant SV, Robinson GC, et al. Association of upper gastrointestinal toxicity of non-steroidal anti-inflammatory drugs with continued exposure: Cohort study. BMJ. 1997;315:1333-1337.
11. 11. Garciá-Rodríguez LA, Cattaruzzi C, Troncon MG, et al. Risk of hospitalization for upper gastrointestinal tract bleeding associated with ketorolac, other nonsteroidal anti-inflammatory drugs, calcium antagonists and other hypertensive drugs. Arch Intern Med. 1998;158:33-39.
12. 12. Agrawal NM, Van Kerckhove HEJM, Erhardt LJ, et al. Misoprostol coadministered with diclofenac for prevention of gastroduodenal ulcers. A one-year study. Dig Dis Sci. 1995;40:1125-1131.
13. 13. Roth SH, Bennett RE, Caldron PH, et al. Endoscopic evaluation of the long term effects of diclofenac sodium and naproxen in elderly patients with arthritis. Clin Drug Invest. 1995;9:171-179.
14. 14. Roth SH, Bennett R, Caldron P, et al. Five-year comparative endoscopic evaluation of arthritis patients treated with nabumetone versus naproxen. Arthritis Rheum. 1991;34(Suppl):S157. Abstract C147.
15. 15. Roth SH, Tindall EA, Jain AK, et al. A controlled study comparing the effects of nabumetone, ibuprofen, and ibuprofen plus misoprostol on the upper gastrointestinal tract mucosa. Arch Intern Med. 1993;153:2565-2571.
16. 16. Taha AS, Hudson N, Hawkey CJ, et al. Famotidine for the prevention of gastric and duodenal ulcers caused by non-steroidal antiinflammatory drugs. NEJM. 1996;334:1435-1439.
17. 17. Borda IT. The spectrum of adverse gastrointestinal effects associated with non-steroidal anti-inflammatory drugs. In: Borda IT, Koff RS, eds. NSAIDs - A Profile of Adverse Effects. Philadelphia: Hanley and Belfus; 1994:25-80.
18. 18. Geis GS, Stead H, Wallemark C-B, et al. Prevalence of mucosal lesions in the stomach and duodenum due to chronic use of NSAIDs in patients with rheumatoid arthritis or osteoarthritis, and interim report on prevention by misoprostol of diclofenac associated lesions. J Rheumatol. 1991;18(Suppl 28):11-14.
19. 19. Fleiss JL. Statistical Methods for Rates and Proportions. 2nd ed. New York: John Wiley & Sons; 1981:143-146.
20. 20. Akdamar K, Ertan A, Agrawal NM, et al. Upper gastrointestinal endoscopy in normal asymptomatic volunteers. Gastrointest Endosc. 1986;32:78-80.
21. 21. Inmaki T, Varis K, Siurala M. Morphological, functional and immunological state of the gastric mucosa in gastric carcinoma families. Scand J Gastroenterol. 1979;14:801-812.
22. 22. Lanza FL, Davis RE. Asymptomatic ulcers and erosions occur in normal volunteer populations. Am J Gastroenterol. 1984;79:820. Abstract.
23. 23. Collins AJ, Davies J, Dixon ASTJ. Contrasting presentation and findings between patients with rheumatic complaints taking nonsteroidal antiinflammatory drugs and a general population referred for endoscopy. Br J Rheumatol. 1986;25:50-53.
24. 24. Griffin MR, Piper JM, Daugherty JR, et al. Nonsteroidal anti-inflammatory drug use and increased risk for peptic ulcer disease in elderly persons. Ann Intern Med. 1991;114:257-263.
25. 25. Silverstein FE, Graham DY, Senior JR, et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs: A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1995;123:241-249.
26. 26. Graham DY, Agrawal NM, Roth SH. Prevention of NSAID-induced gastric ulcer with misoprostol: Multicentre, double-blind, placebo-controlled trial. Lancet. 1998;2:1277-1280.
27. 27. Pérez Gutthann S, Garciá-Rodríguez LA, Raiford DS. Individual nonsteroidal anti-inflammatory drugs and other risk factors for upper gastrointestinal bleeding and perforation. Epidemiology. 1997;8:18-24.
28. 28. Henry D, Lin LL-Y, Garciá-Rodríguez LA, et al. Variability in risk of gastrointestinal complications with individual anti-inflammatory drugs: Results of a collaborative meta-analysis. BMJ. 1996;312:1563-1566.
29. 29. Singh G, Ramey DR, Morfeld D, et al. Gastrointestinal tract complications of nonsteroidal anti-inflammatory drug treatment in rheumatoid arthritis. A prospective observational cohort study. Arch Intern Med. 1996;156:1530-1536.
30. 30. Lipsky PE, Isakson PC. Outcome of specific COX-2 inhibition in rheumatoid arthritis. J Rheumatol. 1997;24(Suppl 49):9-14.
31. 31. Simon LS, Lanza FL, Lipsky PE, et al. Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase 2 inhibitor: Efficacy and safety in two placebo-controlled trials in osteoarthritis and rheumatoid arthritis, and studies of gastrointestinal and platelet effects. Arthritis Rheum. 1998;41:1591-1602.